Global Immune Checkpoint Inhibitors Biomarkers & Clinical Trials Insight 2028 Report Highlights:
- Global Immune Checkpoint Inhibitors Market Opportunity: > USD 30 Billion
- Immune Checkpoint Inhibitors Clinical Trials Insight: CTLA-4, LAG3, PD-1/PD-L1, TIGIT Inhibitors
- Immune Checkpoint Inhibitors Clinical Trials Insight: > 300 Drugs In Trials
- Biomarkers sourced During clinical Trials
- Biomarkers Insight By Immune Checkpoint Inhibitors Classification
- Insight On Biomarkers Sourced From Trials By Drugs & Indication
- Biomarker Name & Function Insight By Immune Checkpoint Inhibitor Drug
- Biomarker Insight Based On Drugs In Multiple Trials Phase & Multiple Indication
Download Report: https://www.kuickresearch.com/report-immune-checkpoint-inhibitors-biomarkers
Immune checkpoint inhibitor therapy is emerging as shining star in the management of cancer. During the therapy, it is necessary to continuously monitor the patient for immune related adverse events. To overcome this, research studies are now focused on the identification of biomarkers. Biomarkers are any biological indicator that reflects disease status but may not necessarily be involved in the disease process itself. The number of potential biomarkers is increasing daily with the advent of genomics, proteomics, metabolomics and other sophisticated imaging technologies. If properly validate, biomarkers can offer great use in drug development. They can aid patient selection, by allowing stratification and risk assessment, and can also predict treatment responses based on the expression of surrogate markers.
Several potential biomarkers from immune system have been identified for immune checkpoint inhibitor therapy including neutrophils, lymphocytes, cytokines, tumor-specific antibodies, and antigen-reactive T cells. Although these have shown encouraging response, these are not highly specific to cancer cells. Therefore, research studies have recently identified tumor associated biomarkers including tumor mutational burden, cytotoxic T-lymphocyte antigen 4 (CTLA-4), programmed cell death 1 (PD-1), programmed cell death-ligand 1 (PD-L1), microsatellite stability, and others. Apart from this, the advancement in the field of genome fingerprinting has led to identification of several other biomarkers which are present in clinical trials.
Nowadays, Artificial intelligence (AI), deep learning (DL), and machine learning (ML) are also being used for the cancer biomarker discovery. For instance, a strategic alliance between pharmaceutical companies and the Center for Computational Imaging and Personalized Diagnostics (CCIPD) at Case Western Reserve University has led to the development of artificial intelligence (AI) tools to benefit patients with non-small cell lung cancer (NSCLC) based on an analysis of routine tissue biopsy images, according to new research. During this, scientists utilized artificial intelligence to identify biomarkers from biopsy images for patients with NSCLC, as well as gynecologic cancers that help predict the response to immunotherapy and clinical outcomes, including survival.
The companies have also launched several biomarker tests for the immune checkpoint inhibitor therapy. For instance, Oxford BioDynamic has developed novel Checkpoint inhibitor Response Test (CiRT) clinical blood test. This test predicts the likelihood of a cancer patient’s response to the widely used class of therapeutics – ICIs – including anti-PD-L1 and anti-PD-1 immunotherapies. Using a routine blood test, rather than an invasive biopsy, CiRT provides fast, personalized guidance for a physician on expected efficacy, enabling a more considered decision whether to begin or continue treatment. The test is available in US and UK and the company is expanding its geographical availability which will drive the growth of market in te coming years.
The future of the cancer immune checkpoint inhibitor biomarker market looks promising with opportunities in the diagnostics, research, prognostics, and risk assessment. The global market is highly competitive and consists of several key players including AstraZeneca, Bristol Myers Squibb, Roche, Novartis AG, Pfizer, and Sanofi, among others. The key players have adopted strategic alliances including partnership, collaboration, or joint ventures to launch their novel product in the market.
As per our report findings, the global immune checkpoint market is expected to surpass US$ 15 Billion by 2028. The high growth rates in the biomarkers market is mainly attributable to several driving factors including the growing importance of companion diagnostics, increasing prevalence of cancer worldwide, increasing funds and grants for biomarker research, and continuous product innovations. Furthermore, upsurge in the public-private funding for target research activities, increasing popularity of personalized medicine, increasing awareness regarding malignancies among patients and rising product innovations and development owing to technological advancements all around the world will extend profitable opportunities for the market players in the forecast period.